HS 10370
Alternative Names: HS-10370Latest Information Update: 21 Sep 2026
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 11 Sep 2026 Jiangsu Hansoh Pharmaceutical plans a phase III trial for Non-small Cell Lung Cancer (Metastatic disease, Late-stage disease, First-line therapy, Monotherapy, Combination therapy)(PO) in October 2026 (NCT07822542)
- 09 May 2025 Jiangsu Hansoh Pharmaceutical plans a phase Ib trial in Solid tumours (Late-stage disease, Combination therapy, Metastatic disease) in China (IV) in May 2025 (NCT06963502)
- 25 Apr 2025 Adverse events and efficacy data from a phase I/II trial in Solid tumours presented 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)